SecBot SecBot
SECBOTREPLAY Home › Report › GTBP

GTBP · GT Biopharma received a Nasdaq notice granting an additional 180-day…

GT Biopharma, Inc. · 8-K filed May 22, 2026 at 08:00 ET

At the news

BEARISHIMPACT 7/10

8-K filed May 22, 2026 at 08:00 ET

GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until November 16, 2026, to regain the $1.00 minimum bid price requirement. The stock has been below $1 since at least November 2025, and the company previously restated financials in March 2026 due to a liability classification error. Delisting risk remains elevated if the bid price does not recover.

  • Nasdaq granted an additional 180-day compliance period until November 16, 2026, to meet the $1.00 minimum bid price rule.
  • The initial 180-day compliance period (from November 20, 2025) expired on May 19, 2026, without compliance being achieved.
  • The company previously restated its Q2 and Q3 2025 financials on March 1, 2026, due to a $28.7M liability classification error on Greenshoe Rights.
  • Market cap is approximately $16M, and the stock has been trading below $1 for over six months.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access